We offer rapid progression from first–in–human to large–scale commercial manufacture for microdosing API. Xcelodose® technology-based systems are an industry standard for rapid and accurate microdosing and an integral part of accelerated pathways to first–in–human studies. Utilization of the Xcelodose® technology can increase speed to clinic and quickly assess new compounds while remaining cost–conscious. Successful clinical studies have shown that, scale up to large–scale manufacture has previously been a limitation. When micro–dosing with the innovative Harro Höfliger Modu–C Mid Speed Encapsulator, these limitations are no longer an impediment to scale–up and commercialization.
We offer a range of multiparticulate (MP) technologies to support your drug delivery development. MPs offer flexibility in release of the drug and work for single and multiple drug combinations. MPs can also support modified release, immediate release, high-dose actives, bioavailability enhanced and taste and odor masked drug products.